65,437 trials
Low Back Pain
Primary: Change From Baseline to Week 16 in the Average Daily Low Back Pain Index Numeric Rating Scale (LBPI NRS) Score — -1.7; -2.0; -2.5; -2.4 Scores on a scale — p=0.3876
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Patients Across Different Lung Function Categories (% FVC (Forced Vital Capacity)) — 57.0; 38.4; 4.7 Percentage of Patients (%)
Opioid Use Disorder
Primary: Subjects With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period-Overall Safety Population — 131; 12; 58; 2 participants
Gastroesophageal Reflux Disease
Primary: Number of Gastroesophageal Refluxes — 42.4 refluxes — p=0.000002
Autism
Primary: Stool Microbiota Composition Change During Prebiotic Only Treatment — 2; 3; 1; 0 Participants
Bladder Cancer · Carcinoma, Transitional Cell · Renal Pelvis Cancer
Primary: Recommended Dose of Enzalutamide — 160 mg
Epilepsy · Dravet Syndrome
Primary: Change In Convulsive Seizures During The Treatment Period Compared To Baseline — 48.7; 45.7; 26.9 percentage reduction — p=0.0299
Neck Pain, Posterior
Primary: Plasma Concentration of Oxytocin — 154.5; 158.8 ug/ml
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Primary: Relative Bioavailability of Tiotropium With GSP304 in Comparison to SPIRIVA RESPIMAT 5 μg Based on CmaxSS — 4.10; 8.00; 21.80; 14.00 pg/mL
Basic Science
Primary: Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Subjective Responses to…
Cardiac Arrest · Metabolic Acidosis
Primary: Return of Spontaneous Circulation (ROSC) — 4; 16 ROSC percents of each group
Severe Osteopetrosis
Primary: Number of Patients Who Achieved Donor Cell Engraftment — 5; 0 Participants
Lupus Erythematosus, Systemic
Primary: Number of Particpants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 170; 50 Participants
Glioblastoma · Cancer of Brain and Nervous System · Glioblastoma Multiforme
Primary: Number of Dose-limiting Toxicities (DLTs) — 0; 0; 0; 1 Number of DLT observed
Amyotrophic Lateral Sclerosis
Primary: Acceptance Rate of Early Non-invasive Positive Pressure Ventilation (NIPPV) Treatment. — 0; 23; 35 Participants